Optimal Protocols for the Anti-VEGF Tumor Treatment

被引:2
|
作者
Poleszczuk, J. [1 ]
Piotrowska, M. J. [2 ]
Forys, U. [2 ]
机构
[1] Univ Warsaw, Coll Inter Fac Individual Studies Math & Nat Sci, PL-02089 Warsaw, Poland
[2] Univ Warsaw, Fac Math Informat & Mech, PL-02097 Warsaw, Poland
关键词
angiogenesis; bevacizumab; optimal control; cancer; ANTIANGIOGENIC THERAPY; ANGIOGENESIS; CANCER; MODEL;
D O I
10.1051/mmnp/20149412
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer treatment using the antiangiogenic agents targets the evolution of the tumor vasculature. The aim is to significantly reduce supplies of oxygen and nutrients, and thus starve the tumor and induce its regression. In the paper we consider well established family of tumor angiogenesis models together with their recently proposed modification, that increases accuracy in the case of treatment using VEGF antibodies. We consider the optimal control problem of minimizing the tumor volume when the maximal admissible drug dose (the total amount of used drug) and the final level of vascularization are also taken into account. We investigate the solution of that problem for a fixed therapy duration. We show that the optimal strategy consists of the drug-free, full-dose and singular (with intermediate values of the control variable) intervals. Moreover, no bang-bang switch of the control is possible, that is the change from the no-dose to full-dose protocol (or in opposite direction) occurs on the interval with the singular control. For two particular models, proposed by Hahnfeldt et al. and Ergun et al., we provide additional theorems about the optimal control structure. We investigate the optimal controls numerically using the customized software written in MATLAB (R), which we make freely available for download. Utilized numerical scheme is based on the composition of the well known gradient and shooting methods.
引用
收藏
页码:204 / 215
页数:12
相关论文
共 50 条
  • [1] Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions
    Finley, Stacey D.
    Popel, Aleksander S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (11): : 802 - 811
  • [2] Anti-VEGF Treatment of Glaucoma
    Bendel, Rick E.
    CURRENT DRUG THERAPY, 2012, 7 (02) : 126 - 130
  • [3] Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
    Bagri, Anil
    Berry, Leanne
    Gunter, Bert
    Singh, Mallika
    Kasman, Ian
    Damico, Lisa A.
    Hong Xiang
    Schmidt, Maike
    Fuh, Germaine
    Hollister, Beth
    Rosen, Oliver
    Plowman, Greg D.
    CLINICAL CANCER RESEARCH, 2010, 16 (15) : 3887 - 3900
  • [4] Tumor refractoriness to anti-VEGF therapy
    Ribatti, Domenico
    ONCOTARGET, 2016, 7 (29) : 46668 - 46677
  • [5] Effect of local anti-VEGF antibody treatment on tumor microvessel permeability
    Lichtenbeld, HC
    Ferarra, N
    Jain, RK
    Munn, LL
    MICROVASCULAR RESEARCH, 1999, 57 (03) : 357 - 362
  • [6] Anti-VEGF Treatment of Corneal Neovascularization
    Keating, Anne M.
    Jacobs, Deborah S.
    OCULAR SURFACE, 2011, 9 (04): : 227 - 238
  • [7] Anti-VEGF Treatment in Corneal Diseases
    Giannaccare, Giuseppe
    Pellegrini, Marco
    Bovone, Cristina
    Spena, Rossella
    Senni, Carlotta
    Scorcia, Vincenzo
    Busin, Massimo
    CURRENT DRUG TARGETS, 2020, 21 (12) : 1159 - 1180
  • [8] Anti-VEGF Treatment of Diabetic Retinopathy
    Wong, Keye
    CURRENT DRUG THERAPY, 2012, 7 (02) : 96 - 100
  • [9] Anti-VEGF agents in the treatment of RVO
    Rehak, Matus
    ACTA OPHTHALMOLOGICA, 2013, 91
  • [10] Anti-VEGF antibody treatment reduces tumor vascular permeability to macromolecules.
    Yuan, F
    Dellian, M
    Ferrara, N
    Jain, RK
    FASEB JOURNAL, 1996, 10 (03): : 322 - 322